Ana de Barros, PhD, managing science editor —

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

New Alzheimer’s Drug Shows Positive Dose-Response in Phase 2 Trial

Anavex Life Sciences Corp. reported that a positive dose-response relationship has been observed in its ongoing Phase 2a clinical trial of ANAVEX 2-73 as a potential treatment for mild-to-moderate Alzheimer’s disease (AD). The announcement came as part of a planned, interim study analysis. The ANAVEX 2-73 Phase 2a study is a multicenter trial…

Alzheimer’s Drug Moves into Phase 1 Safety Study

Tetra Discovery Partners, in collaboration with the NIH Blueprint Neurotherapeutics Network, announced the start of Phase 1 safety trials of BPN14770, a drug Tetra is developing as a potential treatment for neurological disorders such as Alzheimer’s disease (AD) and one that aims to both improve memory and slow disease progression. The NIH Blueprint Neurotherapeutics…

Alzheimer’s Review Highlights Importance of Epigenetic Changes

A recent review discussed how genes implicated in aging and Alzheimer’s disease exhibit epigenetic changes, indicating the same changes might exert a pathogenic role in dementia. The study, titled “Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response,” was published in the International Journal of Molecular…

High Stress May Cause Alzheimer’s in Elderly

High levels of stress can increase the likelihood of elderly people developing mild cognitive impairment — usually a precursor to Alzheimer’s disease. These results are reported in a study titled “Influence of Perceived Stress on Incident Amnestic Mild Cognitive Impairment: Results From the Einstein Aging Study,” published in the…

Alzheimer’s Risk Linked to Prostate Cancer Therapy in Study

Men undergoing androgen deprivation therapy (ADT) for prostate cancer  could be almost twice as likely to be diagnosed with Alzheimer’s disease (AD) than those not treated with ADT. The findings, in a study published in the Journal of Clinical Oncology, also show that the risks of developing Alzheimer’s might continue…

Aerobic Exercise May Reverse Aging Effects Related to Alzheimer’s Disease

Results from a recent study presented at the 8th International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) revealed that aerobic exercise improves brain function and reduces neurodegeneration markers in older adults at risk for Alzheimer’s disease (AD). Study results also indicate that aerobic exercise may be a potential disease-modifying intervention…

AD Learning And Memory Loss Problems Mimic Jet Lag

Findings from a recent study published in the Journal of Alzheimer’s Disease revealed that chemical alterations in brain cells triggered by disruptions in the body’s day-night cycle may be an underlying cause of the memory and learning loss observed in Alzheimer’s disease (AD). The study, conducted by University of California researchers,…